Focused On-demand Library for Large ribosomal subunit protein mL53

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96EL3

UPID:

RM53_HUMAN

Alternative names:

39S ribosomal protein L53, mitochondrial

Alternative UPACC:

Q96EL3

Background:

The Large ribosomal subunit protein mL53, also known as 39S ribosomal protein L53, mitochondrial, plays a crucial role in the mitochondrial ribosome. Its primary function is to facilitate protein synthesis within the mitochondria, a process essential for cellular energy production and metabolic functions. The protein's unique structure and mitochondrial localization underscore its importance in the ribosomal machinery, contributing to the efficient translation of mitochondrial genes.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein mL53 could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key player in cellular metabolism and energy production, areas that are often implicated in a variety of diseases. Exploring its mechanisms further could lead to breakthroughs in treating metabolic disorders and mitochondrial diseases.